• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OpGen, Inc. - Common Stock (NQ:OPGN)

1.960 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OpGen, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
April 23, 2024
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Announces Acquisition of Preferred Stock by David Lazar
March 25, 2024
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
October 12, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
Navigating the Roller Coaster of Recent Penny Stock Surges
October 08, 2023
Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks. 
Via MarketBeat
News headline image
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
August 07, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
August 03, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
August 03, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
July 19, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
June 26, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
June 22, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference
June 20, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
May 08, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Announces Closing of $3.5 Million Public Offering
May 04, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Announces Pricing of $3.5 Million Public Offering
May 01, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
April 26, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
April 18, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
April 18, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
April 05, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
April 03, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 30, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 29, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
March 22, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth
March 01, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Announces Exercise of All Prefunded Warrants
February 17, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen subsidiary Ares Genetics announces granting of key patent in China
January 26, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
January 18, 2023
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
January 17, 2023
Successful delivery of milestones triggers milestone payment 
From OpGen, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap